Gland Pharma share price
You have to be logged in to add this to Watchlist.- ₹1,445.00(0.12%)April 17, 2025 15:29:41 PM IST
- NSE
- BSE
- Vol : 147.71K (NSE + BSE)Last 20 day avg : 571.94 K
Gland Pharma is trading 0.12% upper at Rs 1,445.00 as compared to its last closing price. Gland Pharma has been trading in the price range of 1,454.60 & 1,422.45. Gland Pharma has given -18.54% in this year & 1.68% in the last 5 days. Gland Pharma has TTM P/E ratio 41.61 as compared to the sector P/E of 29.14.There are 10 analysts who have initiated coverage on Gland Pharma. There are 4 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 204.69 Crores in its last quarter.Listed peers of Gland Pharma include Piramal Pharma (-0.74%), J B Chemicals And Pharmaceutical (1.01%), Gland Pharma (0.12%).The Mutual Fund holding in Gland Pharma was at 31.16% in 31 Mar 2025. The MF holding has decreased from the last quarter. The FII holding in Gland Pharma was at 6.90% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Apr 20, 2025, 05:06 PM UTC
- Dividend YieldHigher than industry1.38Annual dividends as a percentage of the stock price.
- P/BLower than historical values2.74The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values33.90Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.66Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.04The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during December quarter by 10.43% from Rs 1545.16 crore to Rs 1384.05 crore, year-on-year- The company has grown its December quarter profit by 6.69% from Rs 191.86 crore to Rs 204.69 crore, year-on-year
- The debt to equity of the company is higher than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,831.47
- R2
- 2,070.73
- R3
- 2,386.47
- S1
- 1,276.47
- S2
- 960.73
- S3
- 721.47
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Piramal Pharma | Moderately Bearish | 220.15 | -0.74 | 29,186.35 | 479.14 | 3.69 | 0.05 | 32.89 |
| J B Chemicals And Pharmaceutical | Neutral | 1,643.60 | 1.01 | 25,587.11 | 47.23 | 8.74 | 0.74 | 1.14 |
| Gland Pharma | Bearish | 1,445.00 | 0.12 | 23,807.30 | 30.92 | 2.74 | 1.38 | 1.62 |
| Wockhardt | Bullish | 1,401.45 | 0.67 | 22,770.62 | - | 6.46 | - | 31.59 |
| Eris Lifesciences | Bullish | 1,381.70 | -1.11 | 18,813.58 | 47.80 | 7.27 | 0.53 | 26.74 |
- Promoter(s) holds a high stake in the company at 51.83%
- FIIs are invested in this company
- FIIs holding has increased by 1.86 percentage points from previous quarter
- Mutual Funds holding has decreased by 1.21 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-03 | Quarterly Results |
| 2024-11-04 | Quarterly Results |
| 2024-08-06 | Quarterly Results |
| 2024-05-22 | Audited Results & Final Dividend |
| 2024-02-14 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE068V01023
- BSE Code543245
- NSE CodeGLAND
Gland Pharma is trading at 1445.00 as on Thu Apr 17 2025 09:59:41. This is 0.12% upper as compared to its previous closing price of 1443.25.
The market capitalization of Gland Pharma is 23807.30 Cr as on Thu Apr 17 2025 09:59:41.
The average broker rating on Gland Pharma is Hold. The breakup of analyst rating is given below -
- 4 analysts have given a strong buy rating
- 0.00 analysts have given a buy rating
- 1 analysts have given a hold rating
- 3 analysts have given a sell rating
- 2 analysts have given a strong sell rating
The 52 wk high for Gland Pharma is 2220.95 whereas the 52 wk low is 1200.00
Gland Pharma can be analyzed on the following key metrics -
- TTM P/E: 41.61
- Sector P/E: 29.14
- Dividend Yield: 1.38%
- D/E ratio: -
Gland Pharma reported a net profit of 772.46 Cr in 2024.
The Mutual Fund Shareholding was 31.16% at the end of 31 Mar 2025.